RUFY1-AS1

Across TCGA pan-cancer cohorts, RUFY1-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of RUFY1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RUFY1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RUFY1-AS1 is over-expressed in tumor, although a few such as BLCA and BRCA show the opposite, repressed pattern.

KIRC, BLCA, and BRCA are the cancer types where RUFY1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RUFY1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.270	<.001	11	view →
BLCA	Male	IV	−1.295	<.001	8	view →
BRCA	Female	All	−0.229	.002	6	view →
LIHC	All	All	+0.118	<.001	5	view →
UCEC	All	All	−0.405	.001	4	view →
KICH	All	All	−0.280	<.001	4	view →
THCA	Male	IV	−0.363	.012	3	view →
CHOL	All	All	+0.571	.002	2	view →
LUSC	All	All	−0.197	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

RUFY1-AS1–KIRC

Open the KIRC breakdown →